Trial Profile
REVACCINATION WITH PREVENAR 13 - CHARACTERIZATION OF THE LATE IMMUNE RESPONSE AFTER POLYSACCHARIDE (REPLAY).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Nov 2021
Price :
$35
*
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Pharmacodynamics
- Acronyms REPLAY
- Sponsors Pfizer
- 08 Dec 2010 Actual end date changed from Dec 2009 to Aug 2010 as reported by ClinicalTrials.gov.
- 05 Mar 2010 Actual number of patients (90) added as reported by ClinicalTrials.gov.
- 05 Mar 2010 Actual end date (1 Dec 2009) added as reported by ClinicalTrials.gov record.